{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:55:21Z","timestamp":1761872121484,"version":"build-2065373602"},"reference-count":48,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015277","name":"Roche Products Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015277","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.clml.2022.07.015","type":"journal-article","created":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T02:29:52Z","timestamp":1659493792000},"page":"e1009-e1018","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Factors Affecting the Clinical Course of Follicular Lymphoma: A Multistate Survival Analysis Using Individual Patient Data from Eight Multicenter Randomized Clinical Trials"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6612-1564","authenticated-orcid":false,"given":"Jesse G.","family":"Dixon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9991-8457","authenticated-orcid":false,"given":"\u00c7a\u011flar","family":"\u00c7a\u011flayan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dai","family":"Chihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie","family":"Dimier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna K.","family":"Wall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9541-8666","authenticated-orcid":false,"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franck","family":"Morschhauser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Marcus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Herold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3078-6131","authenticated-orcid":false,"given":"Eva","family":"Kimby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristie A.","family":"Blum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Ghielmini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9524-3990","authenticated-orcid":false,"given":"Christopher R.","family":"Flowers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.clml.2022.07.015_bib0001","first-page":"443","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"journal-title":"Cancer Stat Facts","article-title":"Surveillance, Epidemiology, End Results Program","year":"2021","key":"10.1016\/j.clml.2022.07.015_sbref0002"},{"key":"10.1016\/j.clml.2022.07.015_bib0003","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.hoc.2020.02.001","article-title":"Epidemiology of follicular lymphoma","volume":"34","author":"Cerhan","year":"2020","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.clml.2022.07.015_bib0004","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.015_bib0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3324\/haematol.2021.278766","article-title":"Time for an individualized approach to first-line management of follicular lymphoma","volume":"107","author":"Cartron","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.07.015_bib0006","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.07.015_bib0007","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab vs. CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomized, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2022.07.015_bib0008","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumor burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomized controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"The Lancet"},{"key":"10.1016\/j.clml.2022.07.015_bib0009","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2022.07.015_bib0010","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1182\/asheducation-2018.1.189","article-title":"Sequencing of therapies in relapsed follicular lymphoma","volume":"2018","author":"Nastoupil","year":"2018","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2022.07.015_bib0011","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/bjh.15149","article-title":"Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study","volume":"184","author":"Link","year":"2019","journal-title":"Br J Hematol"},{"key":"10.1016\/j.clml.2022.07.015_bib0012","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1200\/JCO.18.00400","article-title":"Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts","volume":"37","author":"Sarkozy","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.015_bib0013","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/bjh.17045","article-title":"Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy-free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK)","volume":"192","author":"Moccia","year":"2021","journal-title":"Br J Hematol"},{"key":"10.1016\/j.clml.2022.07.015_bib0014","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood.2019000258","article-title":"Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma","volume":"134","author":"Freeman","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.015_bib0015","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national lymphocare study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.015_bib0016","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1200\/JCO.2012.42.4101","article-title":"Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016","volume":"31","author":"Press","year":"2013","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clml.2022.07.015_bib0017","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1182\/blood.2020010263","article-title":"Validation of POD24 As a robust early clinical endpoint of poor survival in FL from 5225 patients on 13 clinical trials","volume":"139","author":"Casulo","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.015_bib0018","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1200\/JCO.2016.70.8651","article-title":"Thirty-Month complete response as a surrogate endpoint in first-line follicular lymphoma therapy: an individual patient-level analysis of multiple randomized trials","volume":"35","author":"Shi","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.015_bib0019","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.015_bib0020","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.015_bib0021","first-page":"141","article-title":"Empirical transition matrix for nonhomogeneous markov-chains based on censored observations","volume":"5","author":"Aalen","year":"1978","journal-title":"Scandinavian J Statis"},{"year":"2019","series-title":"R: A Language and Environment for Statistical Computing","key":"10.1016\/j.clml.2022.07.015_sbref0022"},{"key":"10.1016\/j.clml.2022.07.015_bib0023","unstructured":"Therneau TM: A package for survival analysis in R. R package version 3.2-13, 2021, https:\/\/CRAN.R-project.org\/package=survival"},{"key":"10.1016\/j.clml.2022.07.015_sbref0024","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2008.18.1495","article-title":"Follicular lymphoma in the United States: first report of the national LymphoCare study","volume":"27","author":"Friedberg","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.015_bib0025","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.annonc.2020.11.008","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dreyling","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2022.07.015_bib0026","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2021.0054","article-title":"NCCN guidelines insights: B-Cell lymphomas, version 5.2021","author":"Zelenetz","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2022.07.015_bib0027","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.19.01073","article-title":"Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study","volume":"37","author":"Bachy","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.015_bib0028","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1200\/JCO.2017.74.5083","article-title":"Continued excellent outcomes in previously untreated patients with follicular lymphoma after treatment with CHOP plus rituximab or CHOP Plus (131)I-tositumomab: long-term follow-up of phase III randomized study SWOG-S0016","volume":"36","author":"Shadman","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.015_bib0029","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1200\/JCO.2017.74.1652","article-title":"Long-Term Results of the FOLL05 trial comparing R-CVP vs. R-CHOP vs. R-FM for the initial treatment of patients with advanced-stage symptomatic follicular lymphoma","volume":"36","author":"Luminari","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.015_bib0030","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-020-0299-0","article-title":"Patterns of change in treatment, response, and outcome in patients with follicular lymphoma over the last four decades: a single-center experience","volume":"10","author":"Mozas","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2022.07.015_bib0031","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1182\/blood-2013-03-491514","article-title":"Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience","volume":"122","author":"Tan","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.015_bib0032","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.015_bib0033","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/ajh.25973","article-title":"Follicular Lymphoma Evaluation Index (FLEX): A new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapy","volume":"95","author":"Mir","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2022.07.015_bib0034","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1470-2045(18)30102-5","article-title":"A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts","volume":"19","author":"Huet","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.07.015_bib0035","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.07.015_bib0036","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/annonc\/mds429","article-title":"Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices","volume":"24","author":"Nooka","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2022.07.015_bib0037","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1182\/blood-2021-145883","article-title":"Event-free and overall survival in over 6000 patients treated with frontline immunochemotherapy for follicular lymphoma between 2002-2018: first report from the international FLIPI24 Consortium","volume":"138","author":"Maurer","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.015_bib0038","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.07.015_bib0039","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.clml.2018.12.019","article-title":"Assessing the Effectiveness of Treatment Sequences for Older Patients With High-risk Follicular Lymphoma With a Multistate Model","volume":"19","author":"Caglayan","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2022.07.015_bib0040","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1200\/JCO.2008.17.2015","article-title":"Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma","volume":"26","author":"Morschhauser","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.015_bib0041","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.015_bib0042","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","article-title":"Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma","volume":"26","author":"Marcus","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.015_bib0043","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","article-title":"Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study","volume":"25","author":"Herold","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.015_bib0044","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.3109\/10428194.2015.1014363","article-title":"Two courses of four weekly infusions of rituximab with or without interferon-alpha 2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas","volume":"56","author":"Kimby","year":"2015","journal-title":"Leukemia Lymphoma"},{"key":"10.1016\/j.clml.2022.07.015_bib0045","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00432-005-0023-2","article-title":"Bendamustine, vincristine and prednisone (BOP) vs. cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19)","volume":"132","author":"Herold","year":"2006","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.015_bib0046","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.015_bib0047","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1200\/JCO.2010.28.4786","article-title":"Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35\/98","volume":"28","author":"Martinelli","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.015_bib0048","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1002\/cncr.32289","article-title":"Randomized trial of ofatumumab and bendamustine vs. ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance)","volume":"125","author":"Blum","year":"2019","journal-title":"Cancer"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502200235X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502200235X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:40:49Z","timestamp":1761871249000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502200235X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":48,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S215226502200235X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.07.015","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factors Affecting the Clinical Course of Follicular Lymphoma: A Multistate Survival Analysis Using Individual Patient Data from Eight Multicenter Randomized Clinical Trials","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}